ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för ruxolitinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

15 träffar

Bibliografisk träff 2012-06-20

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.

Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F.

Blood · comparative study; research support, non-u.s. gov't; research-article; multicenter study; evaluation study; journal article · DOI 10.1182/blood-2012-02-414631

Bibliografisk träff 2012-04-27

U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.

Deisseroth A, Kaminskas E, Grillo J, Chen W, Saber H, Lu HL, Rothmann MD, Brar S, Wang J, Garnett C, Bullock J, Burke LB, Rahman A, Sridhara R, Farrell A, Pazdur R.

Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-12-0653

Bibliografisk träff 2012-04-02

Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.

Mascarenhas J, Hoffman R.

Clin Cancer Res · journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-11-3145

Bibliografisk träff 2012-03-15

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.

Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F.

Blood · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article · DOI 10.1182/blood-2011-12-400051

Bibliografisk träff 2012-03-01

New generation small-molecule inhibitors in myeloproliferative neoplasms.

Passamonti F, Maffioli M, Caramazza D.

Curr Opin Hematol · review; journal article · DOI 10.1097/moh.0b013e32834ff575

Bibliografisk träff 2012-03-01

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G.

N Engl J Med · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1110556

Bibliografisk träff 2012-03-01

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM.

N Engl J Med · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1110557

Bibliografisk träff 2012-03-01

Ruxolitinib for the treatment of myelofibrosis: its clinical potential.

Ostojic A, Vrhovac R, Verstovsek S.

Ther Clin Risk Manag · review-article; journal article · DOI 10.2147/tcrm.s23277

Bibliografisk träff 2012-01-25

JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths.

Tefferi A.

Blood · journal article · DOI 10.1182/blood-2011-11-395228

Bibliografisk träff 2012-01-24

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.

Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, Levy R, Williams W, Gottlieb A.

J Am Acad Dermatol · comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.jaad.2011.12.018

Bibliografisk träff 2012-01-01

Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.

Mascarenhas J, Mughal TI, Verstovsek S.

Curr Med Chem · research support, non-u.s. gov't; research-article; review; journal article · DOI 10.2174/092986712803251511

Bibliografisk träff 2011-10-27

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.

Tefferi A, Pardanani A.

Mayo Clin Proc · video-audio media; brief-report; journal article; case reports · DOI 10.4065/mcp.2011.0518

Bibliografisk träff 2011-09-16

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.

Deshpande A, Reddy MM, Schade GO, Ray A, Chowdary TK, Griffin JD, Sattler M.

Leukemia · research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/leu.2011.255

Bibliografisk träff 2011-09-01

Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.

Ostojic A, Vrhovac R, Verstovsek S.

Future Oncol · research-article; journal article · DOI 10.2217/fon.11.81

Bibliografisk träff 2011-05-20

The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.

Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, McKeever EG, Punwani NG, Williams WV, Yeleswaram S.

J Clin Pharmacol · controlled clinical trial; journal article · DOI 10.1177/0091270011405663